Why the best first market is not the biggest one, but the place where value becomes visible fastest Ask a MedTech, IVD, AI or digital health company where it wants …

Reframing endometriosis Endometriosis has traditionally been described as a chronic gynaecological condition characterised by the presence of endometrial-like tissue outside the uterus.¹ Its most recognised symptoms include dysmenorrhoea, chronic pelvic …

Medical purpose, MiGeL and price discipline From 1 July 2026, Switzerland will introduce reimbursement for selected medical-purpose digital health applications through MiGeL/LiMA. This article explains how companies should approach Swiss …

Price Follows the Patient Pathway Healthcare companies often begin their pricing story in the wrong place. They start with the product. They describe the device, the assay, the implant, the …

Why choosing the wrong French pathway can damage evidence, pricing, adoption and investor confidence France is one of Europe’s most attractive markets for medtech, diagnostics, digital health and AI. It …

In healthcare, evidence only creates value when it answers the question the payer, HTA body, commissioner, hospital, regulator or investor is actually asking. Many healthtech companies do not fail because …